|Awarded On||February 19, 2014|
|Title||Androgen Receptor N-Terminus Blocker Program for Prostate Cancer|
|Program||Product Development Research|
|Award Mechanism||Company Relocation|
|Institution/Organization||ESSA Pharma Inc.|
|Principal Investigator/Program Director||David Wood|
|Cancer Sites||Bone, Other, Prostate|
ESSA Pharma Inc. (ESSA) intends to treat castrate-resistant prostate cancer (CRPC). Growth of prostate cancer cells is driven by male hormones. ESSA’s drugs block the hormone-fueled growth of prostate cancer tumors by an entirely novel mechanism. Specifically, our drugs covalently block the N-terminus of the androgen receptor, preventing activation of the receptor by any means. Thus our drugs may overcome all of the known mechanisms for hormone-therapy resistance.
Our goal is that all men with recurrent prostate cancer will enjoy more months or even years of progression-free lifespan than current therapy offers. ESSA is currently in the clinical candidate selection stage, and expects to c...